News Category
In vitro ADME studies are critical for early assessment of drug candidates, and Creative Bioarray offers comprehensive services to help pharmaceutical...
GeoVax's enhanced MVA-X vaccine provides durable single-dose protection against highly pathogenic Clade I mpox in preclinical models, potentially simp...
Onco-Innovations is aligning manufacturing, preclinical, and clinical planning for its lead cancer candidate ONC010, aiming to disrupt DNA repair in c...
VERAXA Biotech appoints Raju Willener as CFO to bolster financial strategy as it advances its BiTAC oncology pipeline, signaling a push toward clinica...
Apimeds Pharmaceuticals US, Inc. has enlisted IBN to enhance corporate communications, aiming to raise awareness of its MindWave Innovations subsidiar...
Regentis Biomaterials CEO Dr. Ehud Geller discusses the company's GelrinC cartilage repair product, its U.S. pivotal trial, and European commercializa...
Silo Pharma received a U.S. patent Notice of Allowance for its intranasal PTSD treatment SPC-15, strengthening its intellectual property portfolio and...
Regentis Biomaterials moves its off-the-shelf knee cartilage implant GelrinC into a pivotal U.S. and European study, potentially addressing a 470,000-...
Researchers are exploring accelerated biological aging as a potential explanation for the increasing incidence of cancer in adults under 55, a trend t...
VERAXA Biotech's appointment of Raju Willener as CFO brings decades of capital markets expertise to help drive the company's novel BiTAC oncology pipe...
Regentis Biomaterials' GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, is advancing through clinical development wit...
Med-X is positioning its Nature-Cide natural pest-control brand as a key growth driver as it prepares for a Nasdaq listing, with recent OMRI certifica...
Telomir Pharmaceuticals' Telomir-Zn inhibits growth in human and canine osteosarcoma cell lines, suggesting a potential translational pathway for both...
The FDA's clearance of Quantum BioPharma's IND application for Lucid-MS allows the company to proceed directly into a Phase 2 trial, potentially accel...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial aims to generate independent, standardized data t...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNA gene therapy can restore full-length dystrophin and im...
Creative Biolabs has expanded its lipid-based delivery system capabilities to help researchers overcome stability, targeting, and controlled release b...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing solutions, offering researchers advanced tools to overcome sample process...
A comprehensive review reveals that the tumor microenvironment actively reprograms natural killer cells into distinct subsets with specialized functio...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, highlighting...
Regentis Biomaterials reported first half 2026 results, highlighting progress in its Phase III GelrinC trial, a 400% manufacturing yield increase, and...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class drug that aims to protect and rebuild the myelin ...
TransCode Therapeutics announced the retirement of CFO Tom Fitzgerald and the immediate appointment of John Tattory as interim CFO, a change that coul...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its novel BiTAC® T-cell engager pl...
Quantum BioPharma's Lucid-MS has received FDA clearance to proceed to a Phase 2 trial for multiple sclerosis, potentially offering a novel approach th...
Quantum BioPharma's Lucid-MS becomes the first myelin-repair therapy to enter clinical testing for multiple sclerosis, potentially transforming a mult...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and p...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the...
Onco-Innovations' CMO detailed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and has shown promising preclinical ...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance for a Phase 2 trial in multiple sclerosis, potentially offer...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving record confinement pressures and attracting new research cov...
Kairos Pharma's CEO presentation at a major investment conference underscores the company's lead candidate ENV-105, which targets CD105 to reverse dru...
Nutriband's CEO participation in the Nasdaq LaB Biotech Summit underscores the company's strategic positioning in abuse-deterrent transdermal pharmace...
Silo Pharma's participation in the IPAC-RS Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain PTSD treatment, with...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step for a novel myelin-repair approach in multiple sclerosis, drawing an...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its multiple sclerosis drug Lucid-MS, which aims to repair myelin rather than suppress the im...
Helus Pharma's CEO participation at a major investment conference underscores the company's advancing pipeline of novel serotonergic agonists for depr...
GeoVax applauds the new global mpox vaccine stockpile, emphasizing the need for diversified supply and the readiness of its GEO-MVA candidate for Phas...
Voyageur Pharmaceuticals has achieved the first milestone in its iodine production feasibility study with Bayer, securing a $1 million payment that ad...
Greenland Mines announced a Q4 biotech spin-off and acquisition milestones, positioning itself as a key rare earths supplier with a high-value NdPr pr...
VERAXA Biotech's appointment of Raju Willener as CFO brings seasoned financial leadership to support its capital strategy and oncology pipeline develo...
Scinai's strategic shift away from PC111 towards its NanoAb platform and CDMO business underscores a prioritized resource allocation to maximize value...
Onco-Innovations strengthens its oncology pipeline by achieving key manufacturing and regulatory milestones, positioning ONC010 for clinical translati...
OS Animal Health's participation in the Moody Capital conference highlights its strategic push to advance OST-HER2 for canine osteosarcoma, underscori...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a potential breakthrough in MS treatment by targeting myelin repair, a mechani...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a significant step toward a first-in-class therapy that could protect and repa...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Greenland Mines announced plans to spin off its biotech division in Q4 2026, completed the Sarfartoq acquisition, and received Nasdaq approval, positi...
